Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC

Source link :

Combining the bispecific antibody amivantamab (Rybrevant) with chemotherapy in the first- or second-line setting offers ongoing benefit to patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small cell lung cancer (NSCLC) even after disease progression, follow-up analyses of two phase 3 trials suggested. The research — presented over 2 days at the European Lung Cancer […]

Author : News Health

Publish date : 2024-03-28 07:01:35

Copyright for syndicated content belongs to the linked Source.